Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin LAR Depot (20 and 30mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated with Carcinoid Syndrome https://kusajili.com:443/Trial/5GqoTm__XUqUM-se416sQA%24a-phase-iii-prospective-multicentre-randomised-open-parallel-group-comparison-of-lanreotide-autogel-90-and-120mg-administered-b
I have read and accept the terms of use of the site and the Privacy Policy
Send your message